<i>APOE</i> *4 risk‐modifying genes and drug targets in Alzheimer's disease through cell‐type‐specific genomic analyses
Youjie Zeng(Washington University in St. Louis), Michaël E. Belloy(Washington University in St. Louis), Norikazu Hara(Niigata University), Masashi Fujita(Institute of Neuroimmunology of the Slovak Academy of Sciences), M. Ryan Corces(Gladstone Institutes), Vilas Menon(Columbia University), Cyril Pottier(University of Antwerp), Sathesh K. Sivasankaran(Iowa State University), Noah Cook(Washington University in St. Louis), Takeshi Ikeuchi(Niigata University Medical and Dental Hospital), Takashi Morizono(Institute for Medical Informatics and Biostatistics), Carlos Cruchaga(Washington University in St. Louis), Daichi Shigemizu(Tokyo Medical and Dental University), Kouichi Ozaki(National Center for Geriatrics and Gerontology), Valerio Napolioni(Università di Camerino), Michael D. Greicius(Stanford Medicine), Akinori Miyashita(University of Toronto), Yann Le Guen(Stanford University), Chenyu Yang(Washington University in St. Louis), Zachary A. Gardell(Gladstone Institutes)
Cited by 1
Related Papers
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
|Nature Methods|2017|2.8k
A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression
|Nature|2011|2k
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis
|Nature Genetics|2021|1.5k
The chromatin accessibility landscape of primary human cancers
|Science|2018|1.4k